Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00146913
Status:
UNKNOWN
Last Update Posted:
2007-04-27
First Post:
2005-09-05
Brief Title:
AFR10 - Combination Therapy of Imatinib Mesylate IM Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Organization Data
Organization:
Hospices Civils de Lyon
Class:
OTHER
Study ID:
2003317
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Hospices Civils de Lyon
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None